The Claim
GLP-1 receptor agonist use is associated with higher mitochondrial coupling efficiency in the myocardium of heart transplant recipients, as demonstrated by an increased respiratory control ratio (2.43 ± 0.5 vs. 1.8 ± 0.16, p = 0.01) and reduced leak respiration (38.09 ± 15.29 vs. 57.94 ± 16.65, p = 0.02), indicating improved mitochondrial membrane integrity in this population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People who've had heart transplants and take GLP-1 drugs might have healthier heart cell energy factories, because their cells use energy more efficiently and waste less fuel.
See the scientific wording
GLP-1 receptor agonist use is associated with higher mitochondrial coupling efficiency in the myocardium of heart transplant recipients, as evidenced by a higher respiratory control ratio (RCR: 2.43 ± 0.5 vs. 1.8 ± 0.16, p = 0.01) and lower leak respiration (38.09 ± 15.29 vs. 57.94 ± 16.65, p = 0.02), suggesting improved mitochondrial membrane integrity in this population.
What the research says
1 studyThe study looked at heart muscle samples from people who had heart transplants and found that those taking GLP-1 receptor agonists had healthier energy-producing parts of their cells, which matches what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.